{"id":"NCT02283294","sponsor":"University of South Florida","briefTitle":"Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation","officialTitle":"Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04","primaryCompletion":"2019-06","completion":"2019-06","firstPosted":"2014-11-05","resultsPosted":"2021-11-30","lastUpdate":"2021-11-30"},"enrollment":91,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Transient Ischemic Attack","Stroke","Atrial Fibrillation"],"interventions":[{"type":"DRUG","name":"Apixaban","otherNames":[]},{"type":"DRUG","name":"Warfarin","otherNames":[]}],"arms":[{"label":"Apixaban","type":"EXPERIMENTAL"},{"label":"Warfarin","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate if Apixaban will decrease the complication of having another stroke for people who have atrial fibrillation if initiated earlier than standard of care.","primaryOutcome":{"measure":"Number of Participants With a Composite Endpoint of Fatal Stroke, Recurrent Ischemic Stroke, or TIA","timeFrame":"180 days","effectByArm":[{"arm":"Apixaban","deltaMin":7,"sd":null},{"arm":"Warfarin","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":null},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":["36907985","33626904","31620067"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":41},"commonTop":["Bilateral Lower Extremity Edema","Dizziness","Fatigue","Intermittent Headaches","Asymptomatic Bleed"]}}